Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARIFY MS Extension
NCT04776213Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 4 trial of cladribine in multiple sclerosis (MS), sponsored by Merck KGaA. Started Feb 2021; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04776213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776213.